Refine by
Blood Product Articles & Analysis
54 news found
MedSource Labs Moves the Needle in the Peripheral Safety IV Market With the announcement of ClearSafe Comfort® and TrueSafe Comfort® Blood Control IV Catheters with groundbreaking active check valve ...
Peripheral blood mononuclear cells (PBMCs), derived from whole blood or leukapheresis, encompass several major immune cell populations including lymphocytes, monocytes, NK cells and dendritic cells. Apheresis material is a PBMC-enriched blood product widely used in cell therapy, the maximum shelf life of which is 48h when ...
About Myelofibrosis Myelofibrosis is a type of bone marrow cancer that causes extensive scarring in the bone marrow, which disrupts the body’s normal production of healthy blood cells. The result is a reduction in red blood cells, which can cause weakness and fatigue, and in platelets, which increases the risk of bleeding due to deficient ...
About Myelofibrosis Myelofibrosis is a type of bone marrow cancer that causes extensive scarring in the bone marrow, which disrupts the body’s normal production of healthy blood cells. The result is a reduction in red blood cells, which can cause weakness and fatigue, and in platelets, which increases the risk of bleeding due to deficient ...
ZipThaw is a blood product thawer that uses revolutionary dry technology to quickly thaw blood products for patients in need. ...
We’ve been on the road introducing ZipThaw, the revolutionary blood product thawing device, to military and civilian clinicians. ...
ZipThaw is virtually maintenance free and reduces operating costs via lower energy use, reduced maintenance, less labor and almost no blood product waste. Each device has two chambers which work independently to thaw a bag of frozen plasma, so you can maintain high throughput. ...
Additionally, revenue growth was driven by United States Department of Defense (DoD) orders as well as third-party companies contracting with Daxor to conduct blood volume analysis on their products. The Company also reported its successful execution of a Department of Defense contract to build a next-generation portable rapid blood volume ...
Each participant received four different doses of buspirone at different assessment visits: one timed-release 10mg tablet releasing drug after a four-hour delay, one timed-release 10mg tablet releasing drug after an eight-hour delay, one triple-pulse 10mg tablet releasing drug at zero, four and eight hours, and one immediate release 10mg tablet of generic buspirone (the reference ...
The agreement expands upon their current collaboration, begun in 2019 that focused on achieving Good Manufacturing Practice (GMP)-virus manufacturing and establishing processes for adeno-associated virus (AAV) production and purification. GMPs are standards to ensure batches of a medicine are produced with consistently high quality and one of the requirements for therapies to be ...
The abstract posted today details results from the Phase 1/2 clinical trial, demonstrating VX-880 can restore insulin production and glucose control in T1D. Data will be updated and additional information will be presented at the conference. ...
“Pete is a great addition to our team and he is no stranger to our technology, as he conducted the feasibility study of automated production of ACP-01 in 2008. His knowledge and experience in developing highly engineered, commercially focused, automated production systems is a huge advantage as we move to scale production,” stated ...
A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ...
Patient 2 Islet cell function was evaluated at baseline and at Day 90 after VX-880 infusion using a Mixed Meal Tolerance Test (MMTT) with quantification of C-peptide levels, a direct marker for endogenous insulin production. At baseline prior to VX-880 infusion, fasting and stimulated C-peptide levels were undetectable, indicating no endogenous insulin ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces its participation in two upcoming investor conferences. ...
CytoSorbents will now directly commercialize its products in 15 countries, with sales in more than 70 countries worldwide. ...
About CytoSorbents Corporation (NASDAQ: CTSO) CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. Its flagship product, CytoSorb®, is approved in the European Union with distribution in more than 70 countries around the world as an extracorporeal cytokine ...
A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ...
In 2022 Daxor plans on launching its program of new point-of-care blood volume analysis systems, developed under multiple contracts with the US Department of Defense (US DOD) as well as grants from the National Institutes of Health (NIH), a significant leap forward in our market-leading technology and the most important product launch in 20 years for the company. ...
A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ...